Glioblastoma multiforme (GBM), also known as glioblastoma and grade IV astrocytoma, is the most common and most aggressive cancer that begins within the brain. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li Fraumeni syndrome and previous radiation therapy. Typically, treatment involves surgery after which chemotherapy and radiation therapy is used. The medication temozolomide is frequently used as part of chemotherapy, whereas high dose steroids are used to help reduce swelling and decrease symptoms.
Glioblastoma Multiforme Drugs Market 2016-2020 report estimates the global Glioblastoma multiforme drugs market to reach nearly USD 785 Million in 2020, at a CAGR of 13.4% from 2016 to 2020 – iHealthcareAnalyst, Inc.
Visit the Glioblastoma Multiforme Drugs Market 2016-2020 report https://www.ihealthcareanalyst.com/report/glioblastoma-multiforme-drugs-market/
The global Glioblastoma multiforme drugs market segmentation is based on drug types (Bevacizumab, Temozolomide, Carmustine). The global Glioblastoma multiforme drugs market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).
The global Glioblastoma multiforme drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
1.1 Bevacizumab (Avastin)
1.3 Carmustine (BiCNU)
2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World
3. Company Profiles
3.1 AbbVie, Inc.
3.2 Activates GmbH
3.3 Agenus Inc.
3.4 Arog Pharmaceuticals, Inc.
3.5 Bristol-Myers Squibb Company
3.6 Cavion LLC
3.7 Celled Therapeutics Inc.
3.8 CTI BioPharma Corporation
3.9 Cortice Bioscience Inc.
3.10 Eisai Co., Ltd.
3.11 Exelixis Inc.
3.12 F.Hoffman-La Roche Ltd.
3.13 Peregrine Pharmaceuticals, Inc.
3.15 Merrimack Pharmaceuticals, Inc.
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.